Combination treatment of KRH3955 and AMD3100; KRH3955 hinders CXCL12 changes stimulated by AMD3100. (A-C) Mice were administered KRH3955 or vehicle (dash), and 1 hour later, mice were further administered AMD3100 or vehicle (dash). One hour after the last injection, blood was collected for analysis of circulating TNCs (A) and CFU-HPCs (B) (n = 5-8 mice per group). TNCs and CFU-HPCs are shown as cells and colonies per milliliter of blood, respectively. (C) CXCL12 was quantified in PB plasma (n = 5-7 mice per group). CXCL12 levels are shown as picograms per milliliter. Data from 2 independent experiments were represented as mean ± SEM. **P < .01; ***P < .001 (one-way ANOVA with Bonferroni test).